Who is sponsoring NCT03939481?

NCT03939481 is sponsored by SWOG Cancer Research Network.

What drugs are being tested in NCT03939481?

Interventions in NCT03939481: Chemotherapy, Functional Assessment, Questionnaire Administration.

What condition does NCT03939481 study?

NCT03939481 studies Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Lung Non-Small Cell Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage I Ovarian Cancer AJCC v8, Stage IA Ovarian Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage IB Ovarian Cancer AJCC v8, Stage IC Ovarian Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIA Ovarian Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIB Ovarian Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8.

Is NCT03939481 still recruiting?

NCT03939481 is currently active, enrolled. Last updated 13 April 2026.

Last reviewed 2026-04-13 · How we verify

NCT03939481

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer

Active, enrolled Last updated 13 April 2026

What this trial tests

trial testing Chemotherapy in Anatomic Stage I Breast Cancer AJCC v8 in 1,336 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

14 May 2019

Primary endpoint
8 April 2025

1 September 2026

Quick facts

Lead sponsor	SWOG Cancer Research Network
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	1,336
Start date	14 May 2019
Primary completion	8 April 2025
Estimated completion	1 September 2026
Sites	169 locations across Chile, Colombia, United States, Mexico

Drugs / interventions tested

Chemotherapy (chemotherapy) — full drug profile →
Functional Assessment
Questionnaire Administration

Conditions studied

Anatomic Stage I Breast Cancer AJCC v8 — all drugs for Anatomic Stage I Breast Cancer AJCC v8 →
Anatomic Stage IA Breast Cancer AJCC v8 — all drugs for Anatomic Stage IA Breast Cancer AJCC v8 →
Anatomic Stage IB Breast Cancer AJCC v8 — all drugs for Anatomic Stage IB Breast Cancer AJCC v8 →
Anatomic Stage II Breast Cancer AJCC v8 — all drugs for Anatomic Stage II Breast Cancer AJCC v8 →

Sponsor

SWOG Cancer Research Network

Who can join

18 and older, any sex, with Anatomic Stage I Breast Cancer AJCC v8 or Anatomic Stage IA Breast Cancer AJCC v8. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial studies treatment effects on development of chemotherapy-induced peripheral neuropathy in patients with cancer. Treatments for cancer can cause a problem to the nervous system (called peripheral neuropathy) that can lead to tingling or less feeling in hands and feet. Studying certain risk factors, such as age, gender, pre-existing conditions, and the type of treatment for cancer may help doctors estimate how likely patients are to develop the nerve disorder.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221.
Chen CS, Zirpoli G, Barlow WE, Budd GT, et al · · 2023 · cited 19× · PMID 37935109 · DOI 10.6004/jnccn.2023.7062
Co-occurrence and metabolic biomarkers of sensory and motor subtypes of peripheral neuropathy from paclitaxel.
Chen CS, Smith EML, Stringer KA, Henry NL, et al · · 2022 · cited 1× · PMID 35760975 · DOI 10.1007/s10549-022-06652-x
Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage Cancer.
Trivedi MS, Unger JM, Henry NL, Darke AK, et al · · 2026 · PMID 41961500 · DOI 10.1001/jamanetworkopen.2026.4901

Verify or expand the search:

Other trials of Chemotherapy

Trials testing the same drug.

NCT07391774 — Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribocic · Phase 3 · not yet recruiting
NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
NCT07392892 — A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer · Phase 2, PHASE3 · recruiting
NCT07288034 — Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatmen · Phase 2 · recruiting
NCT07078604 — A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negati · Phase 2 · recruiting

Other recruiting trials for Anatomic Stage I Breast Cancer AJCC v8

Currently open trials in the same condition.

NCT07443943 — A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive · Phase 2 · recruiting
NCT07158021 — Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial · Phase 2 · recruiting
NCT06324240 — Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Canc · Phase 1 · recruiting
NCT07407920 — Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial · Phase 2 · active not recruiting
NCT06876714 — ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathol · Phase 3 · recruiting

Other SWOG Cancer Research Network trials

Trials by the same sponsor.

NCT07498205 — Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts · Phase 4 · not yet recruiting
NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07278739 — Testing an Educational Program to Improve Goals of Care Conversations Between Patients and Their Care Teams · NA · not yet recruiting
NCT06769126 — Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM · Phase 2 · recruiting
NCT07018869 — Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colore · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03939481 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SWOG Cancer Research Network
Last refreshed: 13 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03939481.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing